Germany DiGA Fast-Track for Software Vendors

Germany is one of the few markets where a qualifying digital therapeutic can move from regulatory assessment to statutory health insurance reimbursement on a defined Fast-Track. That pathway exists because of the Digitale-Versorgung-Gesetz (DVG — Digital Healthcare Act) and the DiGA (Digitale Gesundheitsanwendungen) framework administered with the Federal Institute for Drugs and Medical Devices (BfArM).

Influrion Solutions is a software development and healthcare IT company that helps founders and compliance officers treat DiGA as a product and evidence program, not a marketing label. If you are building software for German patients and physicians, the Fast-Track decides whether your app is a lifestyle product or a reimbursable care tool. This guide covers what vendors actually need to build: eligibility framing, evidence design, technical and security controls, dossier structure, and post-listing operations.

Germany’s DiGA Fast-Track under the DVG moves vendors from MDR eligibility and indication framing, through a BfArM dossier (evidence, security, IFU), into provisional or permanent directory listing, then physician prescription and GKV reimbursement operations.

What DVG and DiGA actually unlock

The DVG created a legal route for certain CE-marked digital health applications to be listed in the official DiGA directory and prescribed by physicians (and, in defined cases, psychotherapists) with reimbursement through Germany’s statutory health insurance (GKV).

For vendors, three consequences matter more than the politics:

Prescription distribution — listed DiGAs can be prescribed like other covered interventions, which changes go-to-market from consumer acquisition to clinical channel design.
Price negotiation context — provisional listing often starts with a manufacturer price, then moves toward negotiated reimbursement after permanent listing; your commercial model must survive that transition.
Evidence discipline — Germany expects positive care effects (or at least a credible plan to prove them). “Engagement metrics” alone will not carry a dossier.

DiGA is not a generic European passport. Success in Germany does not automatically equal MDR CE marking strategy for every EU member state, nor does it replace GDPR accountability. Treat it as a Germany-specific reimbursement and quality gate on top of your medical-device and privacy foundation.

Are you building a DiGA — or something else?

Before you hire a regulatory writer, classify the product honestly.

Question	If “yes”…	If “no”…
Is the primary purpose a medical purpose under MDR (diagnosis, monitoring, treatment, alleviation…)?	You are likely in SaMD / MDR territory and may be DiGA-eligible if other criteria fit	You may be wellness / lifestyle software — DiGA is usually the wrong path
Is the intended user a patient (or patient + HCP) with a defined indication?	Align indication, IFU, and evidence endpoints early	Vague “digital health for everyone” claims break Fast-Track framing
Can a physician prescribe it as a discrete intervention?	Design onboarding, activation, and adherence for prescription flow	Consumer freemium funnels alone will not match reimbursement ops
Can you show (or plan to show) a positive care effect?	Budget clinical / real-world evidence like a product epic	Delay Fast-Track until the evidence plan is fundable

Positive care effect in DiGA practice typically means medical benefit and/or patient-relevant structural/process improvements (for example adherence, health literacy, coordination) tied to the indication — measured with methods BfArM can evaluate. Influrion’s rule of thumb for product teams: if you cannot name the outcome measure, comparator logic, and analysis plan in one page, you are not ready to apply.

The Fast-Track flow vendors should design for

Think in four stages. Your engineering and compliance calendars should mirror them.

1) Foundation: MDR class, CE mark, QMS, and privacy

DiGA assumes you already behave like a medical device manufacturer where required:

Correct MDR classification and conformity assessment route for your Software as a Medical Device (SaMD).
A living quality management system (ISO 13485-aligned practices are the market norm for serious applicants).
GDPR compliance with a clear legal basis, DPIA where needed, retention, and processor contracts — especially for health data.
Security and interoperability expectations appropriate to a prescribed digital intervention (not a weekend MVP).

Skipping foundation work to “get listed first” is how teams burn a year rewriting architecture after the first BfArM questions arrive.

2) Application dossier and BfArM assessment

The Fast-Track application packages product description, intended use, risk management, evidence (complete or provisional plan), manufacturer information, and technical/security documentation. Expect iterative questions. Build a single source of truth for claims: IFU, app copy, website, and dossier must say the same thing.

3) Provisional vs permanent listing

A common pattern: provisional listing while you complete evidence within a defined window, then permanent listing if requirements are met. Product implications:

Feature freezes around claim-critical flows during the evidence window.
Analytics that can prove endpoints without inventing new PHI-heavy telemetry late.
Version control and change management that auditors can follow (what changed between provisional and permanent?).

4) Prescription, activation, and reimbursement operations

Listing is not the finish line. You need:

Physician-facing materials that match the approved indication.
Patient activation that works with prescription codes / redemption flows used in the German pathway.
Support, pharmacovigilance-style vigilance for software, and complaint handling.
Commercial readiness for price negotiation after evidence matures.

What to build in the product (non-negotiables)

Indication-aligned clinical UX

Map every major screen to the approved intended use. If the dossier says “supports therapy adherence for condition X,” the app must not market itself as a general wellness coach. Influrion recommends a claims matrix: claim → UX surface → data field → evidence measure. Anything outside the matrix is either out of scope or a future variation.

Evidence instrumentation (without turning the app into a data lake)

Instrument the minimum data needed for your endpoints:

Baseline and follow-up patient-reported outcomes (where applicable).
Adherence / usage definitions that match the statistical analysis plan.
Adverse event / safety signal capture appropriate to risk class.
Exportable datasets for researchers with role-based access and audit logs.

Avoid collecting “nice to have” identifiers that expand GDPR risk without advancing endpoints.

Security and trust controls buyers will ask about

German statutory insurers and clinical partners will expect more than a privacy policy PDF:

Control area	Build expectation
AuthN / AuthZ	Strong authentication options; least-privilege roles for patients, HCPs, admins
Encryption	TLS in transit; encryption at rest for health data stores
Logging	Security and access logs with retention; PHI minimization in logs
Vulnerability management	Patch cadence, dependency scanning, documented residual risk
Hosting	Clear data residency story for EU/Germany expectations you commit to commercially
Subprocessors	Inventory, DPAs, change notification process

Interoperability without over-promising

DiGA products vary in how deeply they integrate with practice IT. Decide deliberately:

Standalone app with prescription activation only.
FHIR / structured export for patient summaries.
Deeper EHR workflows only when you can support them operationally.

Do not promise “full Gematik / TI integration” in sales decks unless your roadmap and notified-body / partner plan actually fund it. Over-claiming interoperability is a credibility killer in Germany.

Evidence strategy: provisional honesty beats optimistic timelines

Founders often underestimate evidence duration. A workable vendor plan usually includes:

Endpoint selection tied to indication and literature.
Study design (RCT, pragmatic trial, or other methods acceptable for your claim strength).
Sample size and recruitment reality in German care pathways.
Data management (eCRF / ePRO, monitoring, statistical analysis plan).
Safety reporting and protocol deviations handling.
Publication / report packaging for BfArM — not only an investor slide.

If you need provisional listing to fund the study, say so internally and design the product freeze + budget accordingly. Influrion’s delivery teams treat the evidence window as a release train constraint: claim-critical defects get priority; nice-to-have features wait.

Dossier and vendor checklist (use before you apply)

Common failure modes Influrion sees

Wellness positioning with medical claims — marketing says DiGA; engineering ships a habit tracker with no endpoint design.
Evidence as an afterthought — analytics added after launch cannot reconstruct baseline cohorts.
Claim drift — new features expand intended use without a variation strategy.
Security theater — policies exist; logs, access reviews, and patch evidence do not.
Channel blindness — consumer UA spend with no physician education or prescription support.
Underfunded vigilance — listing succeeds; complaint handling collapses under real users.

Buyer and partner questions you should answer in one sitting

What is the exact indication and exclusion logic?
Is the product CE-marked under MDR for that intended use today?
Provisional or permanent listing target — and what evidence closes the gap?
Where is patient data hosted, and who are the subprocessors?
How do physicians prescribe and how do patients activate?
What happens to price after negotiation with the relevant German bodies?
How do you handle software updates that might affect clinical performance?
What is your incident response and patient communication path?

If your team cannot answer these without a week of archaeology, pause the Fast-Track calendar and fix the operating system of the company first.

FAQ

Is DiGA the same as getting an MDR CE mark?

No. CE marking under MDR addresses conformity as a medical device. DiGA listing addresses whether a qualifying digital application can enter Germany’s directory and reimbursement pathway under DVG rules. Many DiGA candidates need both, but they are different gates.

Can a non-German company apply?

Yes, manufacturers outside Germany can pursue DiGA if they meet applicable requirements (including European representation / economic operator roles as required for devices and market presence). Plan for German-language clinical and support materials early — not the week before submission.

Do we need a randomized controlled trial?

Not every claim strength requires the same design, but weak or poorly justified methods fail. Choose methods that match the positive care effect you assert, and be ready to defend bias, endpoints, and statistics. Optimistic “real-world usage graphs” are not a substitute for a plan BfArM can evaluate.

How is DiGA different from FDA clearance for a digital therapeutic?

Different legal systems, evidence cultures, and reimbursement mechanics. Do not reuse an FDA dossier verbatim as a DiGA package. Re-map intended use, labeling, and evidence to German Fast-Track expectations — then keep a shared core for risk management and software lifecycle where it truly overlaps.

What should we build first if we are 12–18 months from application?

Lock indication and claims matrix, stand up QMS and privacy foundations, instrument evidence-grade analytics, and design prescription/activation UX. Fancy secondary features can wait; claim integrity cannot.

Closing

Germany’s DVG and DiGA Fast-Track reward vendors who build like regulated care partners: clear intended use, CE-ready quality, measurable positive care effects, and operations that survive prescription-scale use. Influrion Solutions helps software teams turn that pathway into concrete architecture, evidence instrumentation, and compliance-ready delivery — not slideware.

If you are scoping a DiGA-ready build or evidence window, contact Influrion to walk through indication framing, technical controls, and a realistic Fast-Track delivery plan.

Germany's Digital Healthcare Act (DVG) and DiGA Fast-Track: What Software Vendors Need to Build